Literature DB >> 28189783

Hormonally up-regulated neu-associated kinase: A novel target for breast cancer progression.

Joelle N Zambrano1, Benjamin A Neely2, Elizabeth S Yeh3.   

Abstract

Hormonally up-regulated neu-associated Kinase (Hunk) is a protein kinase that was originally identified in the murine mammary gland and has been shown to be highly expressed in Human Epidermal Growth Factor Receptor 2 positive (HER2+/ErbB2+) breast cancer cell lines as well as MMTV-neu derived mammary tumor cell lines. However, the physiological role of Hunk has been largely elusive since its identification. Though Hunk is predicted to be a Serine/Threonine (Ser/Thr) protein kinase with homology to the SNF1/AMPK family of protein kinases, there are no known Hunk substrates that have been identified to date. Recent work demonstrates a role for Hunk in HER2+/ErbB2+ breast cancer progression, including drug resistance to HER2/ErbB2 inhibitors, with Hunk potentially acting downstream of HER2/ErbB2 and the PI3K/Akt pathway. These studies have collectively shown that Hunk plays a vital role in promoting mammary tumorigenesis, as Hunk knockdown via shRNA in xenograft tumor models or crossing MMTV-neu or Pten-deficient genetically engineered mouse models into a Hunk knockout (Hunk-/-) background impairs mammary tumor growth in vivo. Because the majority of HER2+/ErbB2+ breast cancer patients acquire drug resistance to HER2/ErbB2 inhibitors, the characterization of novel drug targets like Hunk that have the potential to simultaneously suppress tumorigenesis and potentially enhance efficacy of current therapeutics is an important facet of drug development. Therefore, work aimed at uncovering specific regulatory functions for Hunk that could contribute to this protein kinase's role in both tumorigenesis and drug resistance will be informative. This review focuses on what is currently known about this under-studied protein kinase, and how targeting Hunk may prove to be a potential therapeutic target for the treatment of breast cancer.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Drug resistance; HER2/ErbB2; Hunk; Protein kinase

Mesh:

Substances:

Year:  2017        PMID: 28189783      PMCID: PMC5392418          DOI: 10.1016/j.phrs.2017.02.007

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  46 in total

1.  Protein kinase expression during murine mammary development.

Authors:  L A Chodosh; H P Gardner; J V Rajan; D B Stairs; S T Marquis; P A Leder
Journal:  Dev Biol       Date:  2000-03-15       Impact factor: 3.582

2.  p27 Kip1 inhibits HER2/neu-mediated cell growth and tumorigenesis.

Authors:  H Y Yang; R Shao; M C Hung; M H Lee
Journal:  Oncogene       Date:  2001-06-21       Impact factor: 9.867

Review 3.  Autophagy: detection, regulation and its role in cancer and therapy response.

Authors:  Pia Hönscheid; Kaustubh Datta; Michael H Muders
Journal:  Int J Radiat Biol       Date:  2014-06-25       Impact factor: 2.694

Review 4.  Apoptotic signaling by c-MYC.

Authors:  B Hoffman; D A Liebermann
Journal:  Oncogene       Date:  2008-10-27       Impact factor: 9.867

5.  Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib.

Authors:  Suning Chen; Xingmei Zhu; Hongyu Qiao; Mingxiang Ye; Xiaofeng Lai; Shentong Yu; Likun Ding; Aidong Wen; Jian Zhang
Journal:  Tumour Biol       Date:  2015-09-14

Review 6.  AMPK and HIF signaling pathways regulate both longevity and cancer growth: the good news and the bad news about survival mechanisms.

Authors:  Antero Salminen; Kai Kaarniranta; Anu Kauppinen
Journal:  Biogerontology       Date:  2016-06-03       Impact factor: 4.277

Review 7.  Tumor suppression and promotion by autophagy.

Authors:  Yenniffer Ávalos; Jimena Canales; Roberto Bravo-Sagua; Alfredo Criollo; Sergio Lavandero; Andrew F G Quest
Journal:  Biomed Res Int       Date:  2014-09-18       Impact factor: 3.411

8.  Identification of Nedd4 E3 ubiquitin ligase as a binding partner and regulator of MAK-V protein kinase.

Authors:  Svetlana V Kalinichenko; Keiji Itoh; Elena V Korobko; Sergei Y Sokol; Vladimir L Buchman; Igor V Korobko
Journal:  PLoS One       Date:  2012-06-20       Impact factor: 3.240

9.  Co-Targeting of JNK and HUNK in Resistant HER2-Positive Breast Cancer.

Authors:  Kendall Phelps-Polirer; Melissa A Abt; Danzell Smith; Elizabeth S Yeh
Journal:  PLoS One       Date:  2016-04-05       Impact factor: 3.240

Review 10.  Autophagy and Apoptotic Crosstalk: Mechanism of Therapeutic Resistance in HER2-Positive Breast Cancer.

Authors:  Joelle Zambrano; Elizabeth S Yeh
Journal:  Breast Cancer (Auckl)       Date:  2016-03-13
View more
  2 in total

1.  Extracellular Matrix Imaging of Breast Tissue Pathologies by MALDI-Imaging Mass Spectrometry.

Authors:  Peggi M Angel; Kristina Schwamborn; Susana Comte-Walters; Cassandra L Clift; Lauren E Ball; Anand S Mehta; Richard R Drake
Journal:  Proteomics Clin Appl       Date:  2018-12-14       Impact factor: 3.494

2.  Staurosporine, an inhibitor of hormonally up-regulated neu-associated kinase.

Authors:  Joelle N Zambrano; Christina J Williams; Carly Bess Williams; Lonzie Hedgepeth; Pieter Burger; Tinslee Dilday; Scott T Eblen; Kent Armeson; Elizabeth G Hill; Elizabeth S Yeh
Journal:  Oncotarget       Date:  2018-11-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.